Trial Outcomes & Findings for Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity (NCT NCT01814072)
NCT ID: NCT01814072
Last Updated: 2023-02-01
Results Overview
Estimated mean change from Baseline to Month 6 were obtained from a linear mixed models analysis of variance to account for missing data. All randomized participants were utilized in the model (ITT analysis).
Recruitment status
COMPLETED
Study phase
PHASE2/PHASE3
Target enrollment
562 participants
Primary outcome timeframe
From Baseline to Month 6
Results posted on
2023-02-01
Participant Flow
8593 were screened. 1159 attended orientation. 1078 signed consent. 562 were randomized.
Participants who signed an informed consent were invited to attend a baseline assessment where they were screened further for entry and exclusion criteria. Baseline data was gathered. Participants who continued to be eligible were scheduled for the randomization session where they learned their study assignment.
Participant milestones
| Measure |
1. 12 Calls, PCP
Participant's received biweekly (12) coaching calls, and PCP Reports
|
2. 12 Calls, PCP, MR, Buddy
Participant's received biweekly (12) coaching calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training.
|
3. 12 Calls, PCP, Texts, Buddy
Participant received 12 calls, PCP Reports, Texts, and Buddy Training
|
4. 12 Calls, PCP, Texts, MR
Participant received 12 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
5. 12 Calls, Buddy
Participant received 12 calls, and Buddy Training
|
6. 12 Calls, MR
Participant received 12 calls, and Meal Replacement Recommendations
|
7. 12 Calls, Texts
Participant received 12 calls, and Texts
|
8. 12 Calls, Texts, MR, Buddy
Participant received 12 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
9. 24 Calls, PCP
Participants received 24 calls, and PCP Reports
|
10. 24 Calls, PCP, MR, Buddy
Participants received 24 calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training
|
11. 24 Calls, PCP, Texts, Buddy
Participants received 24 calls, PCP Reports, Texts, and Buddy Training
|
12. 24 Calls, PCP, Texts, MR
Participants received 24 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
13. 24 Calls, Buddy
Participants received 24 calls, and Buddy Training
|
14. 24 Calls, MR
Participants received 24 calls, and Meal Replacement Recommendations
|
15. 24 Calls, Texts
Participants received 24 calls, and Texts
|
16. 24 Calls, Texts, MR, Buddy
Participants received 24 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
17. 12 Calls
Participants received 12 calls
|
18. 12 Calls, MR, Buddy
Participants received 12 calls, Meal Replacement Recommendations, and Buddy Training
|
19. 12 Calls, Texts, Buddy
Participants received 12 calls, Texts, and Buddy Training
|
20. 12 Calls, Texts, MR
Participants received 12 calls, Texts, Meal Replacement Recommendations
|
21. 12 Calls, PCP, Buddy
Participants received 12 calls, PCP Reports, and Buddy Training
|
22. 12 Calls, PCP, MR
Participants received 12 calls, PCP Reports, and Meal Replacement Recommendations
|
23. 12 Calls PCP, Texts
Participants received 12 calls, PCP Reports, and Texts
|
24. 12 Calls, PCP, Texts, MR, Buddy
Participants received 12 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
25. 24 Calls
Participants received 24 calls
|
26. 24 Calls, MR, Buddy
Participants received 24 calls, Meal Replacement Recommendations, and Buddy Training
|
27. 24 Calls, Texts, Buddy
Participants received 24 calls, Texts, and Buddy Training
|
28. 24 Calls, Texts, MR
Participants received 24 calls, Texts, and Meal Replacement Recommendations
|
29. 24 Calls, PCP, Buddy
Participants received 24 calls, PCP Reports, and Buddy Training
|
30. 24 Calls, PCP, MR
Participants received 24 calls, PCP Reports, and Meal Replacement Recommendations
|
31. 24 Calls, PCP, Texts
Participants received 24 calls, PCP Reports, and Texts
|
32. 24 Calls, PCP, Texts, MR, Buddy
Participants received 24 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
18
|
18
|
18
|
18
|
18
|
18
|
18
|
18
|
19
|
18
|
18
|
18
|
18
|
18
|
18
|
18
|
17
|
18
|
17
|
16
|
16
|
17
|
17
|
18
|
17
|
16
|
18
|
17
|
18
|
17
|
17
|
17
|
|
Overall Study
3-mo Visit
|
15
|
18
|
16
|
18
|
15
|
15
|
16
|
18
|
18
|
15
|
18
|
17
|
16
|
16
|
16
|
16
|
16
|
16
|
14
|
13
|
15
|
17
|
15
|
18
|
13
|
14
|
17
|
14
|
15
|
16
|
16
|
17
|
|
Overall Study
Intent to Treat
|
4
|
2
|
3
|
0
|
4
|
6
|
4
|
1
|
3
|
5
|
1
|
2
|
3
|
2
|
3
|
2
|
3
|
1
|
3
|
5
|
2
|
1
|
4
|
1
|
6
|
2
|
2
|
4
|
4
|
3
|
2
|
0
|
|
Overall Study
COMPLETED
|
14
|
16
|
15
|
18
|
14
|
12
|
14
|
17
|
16
|
13
|
17
|
16
|
15
|
16
|
15
|
16
|
14
|
17
|
14
|
11
|
14
|
16
|
13
|
17
|
11
|
14
|
16
|
13
|
14
|
14
|
15
|
17
|
|
Overall Study
NOT COMPLETED
|
4
|
2
|
3
|
0
|
4
|
6
|
4
|
1
|
3
|
5
|
1
|
2
|
3
|
2
|
3
|
2
|
3
|
1
|
3
|
5
|
2
|
1
|
4
|
1
|
6
|
2
|
2
|
4
|
4
|
3
|
2
|
0
|
Reasons for withdrawal
| Measure |
1. 12 Calls, PCP
Participant's received biweekly (12) coaching calls, and PCP Reports
|
2. 12 Calls, PCP, MR, Buddy
Participant's received biweekly (12) coaching calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training.
|
3. 12 Calls, PCP, Texts, Buddy
Participant received 12 calls, PCP Reports, Texts, and Buddy Training
|
4. 12 Calls, PCP, Texts, MR
Participant received 12 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
5. 12 Calls, Buddy
Participant received 12 calls, and Buddy Training
|
6. 12 Calls, MR
Participant received 12 calls, and Meal Replacement Recommendations
|
7. 12 Calls, Texts
Participant received 12 calls, and Texts
|
8. 12 Calls, Texts, MR, Buddy
Participant received 12 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
9. 24 Calls, PCP
Participants received 24 calls, and PCP Reports
|
10. 24 Calls, PCP, MR, Buddy
Participants received 24 calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training
|
11. 24 Calls, PCP, Texts, Buddy
Participants received 24 calls, PCP Reports, Texts, and Buddy Training
|
12. 24 Calls, PCP, Texts, MR
Participants received 24 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
13. 24 Calls, Buddy
Participants received 24 calls, and Buddy Training
|
14. 24 Calls, MR
Participants received 24 calls, and Meal Replacement Recommendations
|
15. 24 Calls, Texts
Participants received 24 calls, and Texts
|
16. 24 Calls, Texts, MR, Buddy
Participants received 24 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
17. 12 Calls
Participants received 12 calls
|
18. 12 Calls, MR, Buddy
Participants received 12 calls, Meal Replacement Recommendations, and Buddy Training
|
19. 12 Calls, Texts, Buddy
Participants received 12 calls, Texts, and Buddy Training
|
20. 12 Calls, Texts, MR
Participants received 12 calls, Texts, Meal Replacement Recommendations
|
21. 12 Calls, PCP, Buddy
Participants received 12 calls, PCP Reports, and Buddy Training
|
22. 12 Calls, PCP, MR
Participants received 12 calls, PCP Reports, and Meal Replacement Recommendations
|
23. 12 Calls PCP, Texts
Participants received 12 calls, PCP Reports, and Texts
|
24. 12 Calls, PCP, Texts, MR, Buddy
Participants received 12 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
25. 24 Calls
Participants received 24 calls
|
26. 24 Calls, MR, Buddy
Participants received 24 calls, Meal Replacement Recommendations, and Buddy Training
|
27. 24 Calls, Texts, Buddy
Participants received 24 calls, Texts, and Buddy Training
|
28. 24 Calls, Texts, MR
Participants received 24 calls, Texts, and Meal Replacement Recommendations
|
29. 24 Calls, PCP, Buddy
Participants received 24 calls, PCP Reports, and Buddy Training
|
30. 24 Calls, PCP, MR
Participants received 24 calls, PCP Reports, and Meal Replacement Recommendations
|
31. 24 Calls, PCP, Texts
Participants received 24 calls, PCP Reports, and Texts
|
32. 24 Calls, PCP, Texts, MR, Buddy
Participants received 24 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
2
|
2
|
2
|
0
|
2
|
3
|
3
|
1
|
2
|
3
|
1
|
2
|
2
|
1
|
2
|
1
|
3
|
1
|
3
|
3
|
2
|
1
|
3
|
1
|
4
|
1
|
1
|
2
|
3
|
3
|
2
|
0
|
|
Overall Study
Withdrawal by Subject
|
2
|
0
|
1
|
0
|
2
|
3
|
1
|
0
|
1
|
2
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
2
|
0
|
0
|
1
|
0
|
2
|
1
|
1
|
2
|
1
|
0
|
0
|
0
|
Baseline Characteristics
Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity
Baseline characteristics by cohort
| Measure |
1. 12 Calls, PCP
n=18 Participants
Participants received biweekly (12) coaching calls, and PCP Reports
|
2. 12 Calls, PCP, MR, Buddy
n=18 Participants
Participants received biweekly (12) coaching calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training.
|
3. 12 Calls, PCP, Texts, Buddy
n=18 Participants
Participants received 12 calls, PCP Reports, Texts, and Buddy Training
|
4. 12 Calls, PCP, Texts, MR
n=18 Participants
Participants received 12 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
5. 12 Calls, Buddy
n=18 Participants
Participants received 12 calls, and Buddy Training
|
6. 12 Calls, MR
n=18 Participants
Participants received 12 calls, and Meal Replacement Recommendations
|
7. 12 Calls, Texts
n=18 Participants
Participants received 12 calls, and Texts
|
8. 12 Calls, Texts, MR, Buddy
n=18 Participants
Participants received 12 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
9. 24 Calls, PCP
n=19 Participants
Participants received 24 calls, and PCP Reports
|
10. 24 Calls, PCP, MR, Buddy
n=18 Participants
Participants received 24 calls, PCP Reports, Meal Replacement Recommendations, and Buddy Training
|
11. 24 Calls, PCP, Texts, Buddy
n=18 Participants
Participants received 24 calls, PCP Reports, Texts, and Buddy Training
|
12. 24 Calls, PCP, Texts, MR
n=18 Participants
Participants received 24 calls, PCP Reports, Texts, and Meal Replacement Recommendations
|
13. 24 Calls, Buddy
n=18 Participants
Participants received 24 calls, and Buddy Training
|
14. 24 Calls, MR
n=18 Participants
Participants received 24 calls, and Meal Replacement Recommendations
|
15. 24 Calls, Texts
n=18 Participants
Participants received 24 calls, and Texts
|
16. 24 Calls, Texts, MR, Buddy
n=18 Participants
Participants received 24 calls, Texts, Meal Replacement Recommendations, and Buddy Training
|
17. 12 Calls
n=17 Participants
Participants received 12 calls
|
18. 12 Calls, MR, Buddy
n=18 Participants
Participants received 12 calls, Meal Replacement Recommendations, and Buddy Training
|
19. 12 Calls, Texts, Buddy
n=17 Participants
Participants received 12 calls, Texts, and Buddy Training
|
20. 12 Calls, Texts, MR
n=16 Participants
Participants received 12 calls, Texts, Meal Replacement Recommendations
|
21. 12 Calls, PCP, Buddy
n=16 Participants
Participants received 12 calls, PCP Reports, and Buddy Training
|
22. 12 Calls, PCP, MR
n=17 Participants
Participants received 12 calls, PCP Reports, and Meal Replacement Recommendations
|
23. 12 Calls PCP, Texts
n=17 Participants
Participants received 12 calls, PCP Reports, and Texts
|
24. 12 Calls, PCP, Texts, MR, Buddy
n=18 Participants
Participants received 12 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
25. 24 Calls
n=17 Participants
Participants received 24 calls
|
26. 24 Calls, MR, Buddy
n=16 Participants
Participants received 24 calls, Meal Replacement Recommendations, and Buddy Training
|
27. 24 Calls, Texts, Buddy
n=18 Participants
Participants received 24 calls, Texts, and Buddy Training
|
28. 24 Calls, Texts, MR
n=17 Participants
Participants received 24 calls, Texts, and Meal Replacement Recommendations
|
29. 24 Calls, PCP, Buddy
n=18 Participants
Participants received 24 calls, PCP Reports, and Buddy Training
|
30. 24 Calls, PCP, MR
n=17 Participants
Participants received 24 calls, PCP Reports, and Meal Replacement Recommendations
|
31. 24 Calls, PCP, Texts
n=17 Participants
Participants received 24 calls, PCP Reports, and Texts
|
32. 24 Calls, PCP, Texts, MR, Buddy
n=17 Participants
Participants received 24 calls, PCP Reports, Texts, Meal Replacement Recommendations, and Buddy Training
|
Total
n=562 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
40.0 years
STANDARD_DEVIATION 8.6 • n=5 Participants
|
43.2 years
STANDARD_DEVIATION 14.2 • n=7 Participants
|
41.7 years
STANDARD_DEVIATION 10.9 • n=5 Participants
|
40.2 years
STANDARD_DEVIATION 11.2 • n=4 Participants
|
31.4 years
STANDARD_DEVIATION 9.1 • n=21 Participants
|
40.5 years
STANDARD_DEVIATION 9.9 • n=8 Participants
|
40.8 years
STANDARD_DEVIATION 12.2 • n=8 Participants
|
39.4 years
STANDARD_DEVIATION 12.9 • n=24 Participants
|
39.5 years
STANDARD_DEVIATION 8.3 • n=42 Participants
|
38.7 years
STANDARD_DEVIATION 8.9 • n=42 Participants
|
39.1 years
STANDARD_DEVIATION 11.2 • n=42 Participants
|
40.6 years
STANDARD_DEVIATION 12.0 • n=42 Participants
|
40.4 years
STANDARD_DEVIATION 9.1 • n=36 Participants
|
36.3 years
STANDARD_DEVIATION 10.6 • n=36 Participants
|
39.8 years
STANDARD_DEVIATION 12.8 • n=24 Participants
|
35.8 years
STANDARD_DEVIATION 11.8 • n=135 Participants
|
38.2 years
STANDARD_DEVIATION 12.0 • n=136 Participants
|
39.2 years
STANDARD_DEVIATION 10.5 • n=44 Participants
|
37.4 years
STANDARD_DEVIATION 10.9 • n=667 Participants
|
32.2 years
STANDARD_DEVIATION 7.1 • n=12 Participants
|
36.7 years
STANDARD_DEVIATION 6.0 • n=12 Participants
|
40.3 years
STANDARD_DEVIATION 10.8 • n=12 Participants
|
40.1 years
STANDARD_DEVIATION 11.6 • n=12 Participants
|
37.9 years
STANDARD_DEVIATION 12.8 • n=11 Participants
|
35.7 years
STANDARD_DEVIATION 9.6 • n=6 Participants
|
47.3 years
STANDARD_DEVIATION 10.2 • n=7 Participants
|
35.1 years
STANDARD_DEVIATION 9.0 • n=7 Participants
|
41.0 years
STANDARD_DEVIATION 10.1 • n=408 Participants
|
39.1 years
STANDARD_DEVIATION 11.7 • n=206 Participants
|
37.2 years
STANDARD_DEVIATION 9.9 • n=16 Participants
|
40.6 years
STANDARD_DEVIATION 12.8 • n=252 Participants
|
39.9 years
STANDARD_DEVIATION 12.0 • n=8 Participants
|
38.9 years
STANDARD_DEVIATION 10.9 • n=269 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
15 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
15 Participants
n=8 Participants
|
15 Participants
n=8 Participants
|
15 Participants
n=24 Participants
|
16 Participants
n=42 Participants
|
15 Participants
n=42 Participants
|
15 Participants
n=42 Participants
|
15 Participants
n=42 Participants
|
15 Participants
n=36 Participants
|
15 Participants
n=36 Participants
|
15 Participants
n=24 Participants
|
15 Participants
n=135 Participants
|
14 Participants
n=136 Participants
|
14 Participants
n=44 Participants
|
14 Participants
n=667 Participants
|
12 Participants
n=12 Participants
|
13 Participants
n=12 Participants
|
14 Participants
n=12 Participants
|
14 Participants
n=12 Participants
|
14 Participants
n=11 Participants
|
14 Participants
n=6 Participants
|
13 Participants
n=7 Participants
|
14 Participants
n=7 Participants
|
14 Participants
n=408 Participants
|
14 Participants
n=206 Participants
|
14 Participants
n=16 Participants
|
13 Participants
n=252 Participants
|
13 Participants
n=8 Participants
|
459 Participants
n=269 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
4 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
4 Participants
n=12 Participants
|
3 Participants
n=12 Participants
|
3 Participants
n=12 Participants
|
3 Participants
n=12 Participants
|
4 Participants
n=11 Participants
|
3 Participants
n=6 Participants
|
3 Participants
n=7 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=408 Participants
|
4 Participants
n=206 Participants
|
3 Participants
n=16 Participants
|
4 Participants
n=252 Participants
|
4 Participants
n=8 Participants
|
103 Participants
n=269 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
12 Participants
n=5 Participants
|
18 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
11 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
18 Participants
n=8 Participants
|
16 Participants
n=8 Participants
|
13 Participants
n=24 Participants
|
16 Participants
n=42 Participants
|
16 Participants
n=42 Participants
|
18 Participants
n=42 Participants
|
17 Participants
n=42 Participants
|
13 Participants
n=36 Participants
|
17 Participants
n=36 Participants
|
17 Participants
n=24 Participants
|
17 Participants
n=135 Participants
|
13 Participants
n=136 Participants
|
16 Participants
n=44 Participants
|
12 Participants
n=667 Participants
|
14 Participants
n=12 Participants
|
13 Participants
n=12 Participants
|
14 Participants
n=12 Participants
|
15 Participants
n=12 Participants
|
16 Participants
n=11 Participants
|
15 Participants
n=6 Participants
|
16 Participants
n=7 Participants
|
18 Participants
n=7 Participants
|
14 Participants
n=408 Participants
|
16 Participants
n=206 Participants
|
15 Participants
n=16 Participants
|
15 Participants
n=252 Participants
|
17 Participants
n=8 Participants
|
489 Participants
n=269 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
4 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
4 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
2 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
2 Participants
n=11 Participants
|
2 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=408 Participants
|
2 Participants
n=206 Participants
|
2 Participants
n=16 Participants
|
1 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
53 Participants
n=269 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
2 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=408 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=16 Participants
|
1 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
20 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
White/Caucasian
|
10 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
16 Participants
n=21 Participants
|
15 Participants
n=8 Participants
|
15 Participants
n=8 Participants
|
10 Participants
n=24 Participants
|
15 Participants
n=42 Participants
|
14 Participants
n=42 Participants
|
14 Participants
n=42 Participants
|
12 Participants
n=42 Participants
|
12 Participants
n=36 Participants
|
15 Participants
n=36 Participants
|
15 Participants
n=24 Participants
|
14 Participants
n=135 Participants
|
13 Participants
n=136 Participants
|
15 Participants
n=44 Participants
|
9 Participants
n=667 Participants
|
14 Participants
n=12 Participants
|
11 Participants
n=12 Participants
|
14 Participants
n=12 Participants
|
12 Participants
n=12 Participants
|
14 Participants
n=11 Participants
|
12 Participants
n=6 Participants
|
13 Participants
n=7 Participants
|
14 Participants
n=7 Participants
|
9 Participants
n=408 Participants
|
13 Participants
n=206 Participants
|
10 Participants
n=16 Participants
|
13 Participants
n=252 Participants
|
16 Participants
n=8 Participants
|
417 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
Black
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
5 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=135 Participants
|
1 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
4 Participants
n=12 Participants
|
3 Participants
n=11 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=7 Participants
|
5 Participants
n=408 Participants
|
4 Participants
n=206 Participants
|
2 Participants
n=16 Participants
|
2 Participants
n=252 Participants
|
1 Participants
n=8 Participants
|
87 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
2 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=11 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=408 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=16 Participants
|
1 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
16 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=408 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=16 Participants
|
0 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
5 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=408 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=16 Participants
|
0 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=269 Participants
|
|
Race/Ethnicity, Customized
Other/Unknown
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
1 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
2 Participants
n=12 Participants
|
1 Participants
n=12 Participants
|
1 Participants
n=11 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=408 Participants
|
1 Participants
n=206 Participants
|
5 Participants
n=16 Participants
|
1 Participants
n=252 Participants
|
0 Participants
n=8 Participants
|
36 Participants
n=269 Participants
|
|
Weight (kg)
|
88.9 Kilograms
STANDARD_DEVIATION 10.6 • n=5 Participants
|
91.2 Kilograms
STANDARD_DEVIATION 14.0 • n=7 Participants
|
87.3 Kilograms
STANDARD_DEVIATION 12.0 • n=5 Participants
|
88.8 Kilograms
STANDARD_DEVIATION 14.0 • n=4 Participants
|
90.4 Kilograms
STANDARD_DEVIATION 11.3 • n=21 Participants
|
90.0 Kilograms
STANDARD_DEVIATION 13.3 • n=8 Participants
|
97.8 Kilograms
STANDARD_DEVIATION 13.3 • n=8 Participants
|
87.3 Kilograms
STANDARD_DEVIATION 13.4 • n=24 Participants
|
94.4 Kilograms
STANDARD_DEVIATION 14.7 • n=42 Participants
|
93.1 Kilograms
STANDARD_DEVIATION 12.9 • n=42 Participants
|
97.6 Kilograms
STANDARD_DEVIATION 14.4 • n=42 Participants
|
88.1 Kilograms
STANDARD_DEVIATION 13.4 • n=42 Participants
|
89.6 Kilograms
STANDARD_DEVIATION 12.9 • n=36 Participants
|
87.2 Kilograms
STANDARD_DEVIATION 13.9 • n=36 Participants
|
94.3 Kilograms
STANDARD_DEVIATION 14.7 • n=24 Participants
|
91.3 Kilograms
STANDARD_DEVIATION 11.3 • n=135 Participants
|
88.4 Kilograms
STANDARD_DEVIATION 13.7 • n=136 Participants
|
90.2 Kilograms
STANDARD_DEVIATION 15.2 • n=44 Participants
|
90.8 Kilograms
STANDARD_DEVIATION 14.8 • n=667 Participants
|
83.3 Kilograms
STANDARD_DEVIATION 9.8 • n=12 Participants
|
92.9 Kilograms
STANDARD_DEVIATION 14.8 • n=12 Participants
|
86.1 Kilograms
STANDARD_DEVIATION 10.5 • n=12 Participants
|
98.0 Kilograms
STANDARD_DEVIATION 15.3 • n=12 Participants
|
90.5 Kilograms
STANDARD_DEVIATION 17.6 • n=11 Participants
|
80.7 Kilograms
STANDARD_DEVIATION 12.2 • n=6 Participants
|
89.8 Kilograms
STANDARD_DEVIATION 9.9 • n=7 Participants
|
90.1 Kilograms
STANDARD_DEVIATION 12.0 • n=7 Participants
|
85.5 Kilograms
STANDARD_DEVIATION 10.8 • n=408 Participants
|
89.7 Kilograms
STANDARD_DEVIATION 13.4 • n=206 Participants
|
93.7 Kilograms
STANDARD_DEVIATION 16.6 • n=16 Participants
|
86.8 Kilograms
STANDARD_DEVIATION 11.5 • n=252 Participants
|
86.1 Kilograms
STANDARD_DEVIATION 16.0 • n=8 Participants
|
90.0 Kilograms
STANDARD_DEVIATION 13.6 • n=269 Participants
|
PRIMARY outcome
Timeframe: From Baseline to Month 6Population: ITT population: all randomized participants with at least one weight value. The decision to analyze all randomized participants together for aim 1, rather than separately by arm, was pre-specified in the the Protocol/Statistical Analysis Plan for the purposes of assessing the main effect of time.
Estimated mean change from Baseline to Month 6 were obtained from a linear mixed models analysis of variance to account for missing data. All randomized participants were utilized in the model (ITT analysis).
Outcome measures
| Measure |
All Reporting Groups
n=562 Participants
All participants regardless of individual randomly assigned combination of On- or Off switched levels of all intervention factors, weight measured at baseline and at Month 6.
|
PCP Reports
Participant's primary care physician was (On) or was not (Off) sent a progress report after the 3 and 6 month assessments.
|
Text Messages
Participants either received (On) or did not receive (Off) push notifications through the app at their preferred time or when they opened the app.
|
Meal Replacements
Participants either received (On) or did not receive (Off) a one week supply of meal replacement bars and shakes. Those who did receive a 1-week supply of meal replacements were provided with recommendations on each coaching call to continue using these products throughout the intervention.
|
Buddy Training
Participant buddies either received (On) or did not receive (Off) additional training.
|
|---|---|---|---|---|---|
|
Weight Change (kg) From Baseline to Month 6, Main Effect of Time
|
-4.8 Kg
Interval -5.3 to -4.4
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: From Baseline to Month 6Population: ITT population: all randomized participants with at least one weight value.
Estimated mean change from Baseline to Month 6 were obtained from a linear mixed models analysis of variance to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as an additional effect beyond that of Outcome Measure 1 (each component has it's own weight loss effect that is above and beyond the weight change calculated in the Outcome Measure 1 analyses).
Outcome measures
| Measure |
All Reporting Groups
n=562 Participants
All participants regardless of individual randomly assigned combination of On- or Off switched levels of all intervention factors, weight measured at baseline and at Month 6.
|
PCP Reports
n=562 Participants
Participant's primary care physician was (On) or was not (Off) sent a progress report after the 3 and 6 month assessments.
|
Text Messages
n=562 Participants
Participants either received (On) or did not receive (Off) push notifications through the app at their preferred time or when they opened the app.
|
Meal Replacements
n=562 Participants
Participants either received (On) or did not receive (Off) a one week supply of meal replacement bars and shakes. Those who did receive a 1-week supply of meal replacements were provided with recommendations on each coaching call to continue using these products throughout the intervention.
|
Buddy Training
n=562 Participants
Participant buddies either received (On) or did not receive (Off) additional training.
|
|---|---|---|---|---|---|
|
Weight Change (kg) From Baseline to Month 6, Time by Factor Interaction
|
.1244 Kg
Interval -0.3026 to 0.5513
|
-.0226 Kg
Interval -0.4495 to 0.4044
|
.0840 Kg
Interval -0.3429 to 0.5109
|
.1081 Kg
Interval -0.3188 to 0.535
|
-.4353 Kg
Interval -0.8622 to -0.0084
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: ITT population: weight loss data from all randomized participants with at least one weight value; combined with cost data for study implementation (staff time, supplies, etc.)
Using the results from primary aim 1, an intervention with only active treatment components with the largest treatment effect that can be obtained for implementation costs of $500 or less was identified and built.
Outcome measures
| Measure |
All Reporting Groups
n=562 Participants
All participants regardless of individual randomly assigned combination of On- or Off switched levels of all intervention factors, weight measured at baseline and at Month 6.
|
PCP Reports
Participant's primary care physician was (On) or was not (Off) sent a progress report after the 3 and 6 month assessments.
|
Text Messages
Participants either received (On) or did not receive (Off) push notifications through the app at their preferred time or when they opened the app.
|
Meal Replacements
Participants either received (On) or did not receive (Off) a one week supply of meal replacement bars and shakes. Those who did receive a 1-week supply of meal replacements were provided with recommendations on each coaching call to continue using these products throughout the intervention.
|
Buddy Training
Participant buddies either received (On) or did not receive (Off) additional training.
|
|---|---|---|---|---|---|
|
Intervention for <$500
|
427 dollars
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsTreatment adherence is a hypothesized mediator that will be operationalized as the number of treatment sessions completed divided by the number of treatment sessions offered (12 or 24)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsSelf-monitoring is a hypothesized mediator that will be operationalized as the number of days recording weight, dietary intake, and physical activity
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsSelf-efficacy is an exploratory mediator that will be assessed to examine treatment effects on confidence about performing two categories of behaviors associated with weight loss: diet and physical activity
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsSelf-regulation is an exploratory mediator that will be assessed using the Three Factor Eating Questionnaire and Treatment Self-Regulation Questionnaire
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsSupportive accountability is an exploratory mediator that will be measured by assessing two constructs that define supportive accountability: therapeutic alliance and perceived autonomy support
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 monthsFacilitation is an exploratory mediator that will be measured by rating how much the tools provided by the study have changed their environment and by the Weight Management Support Inventory
Outcome measures
Outcome data not reported
Adverse Events
Condition 16
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 17
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Condition 18
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 19
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Condition 20
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 21
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 22
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 23
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Condition 24
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 25
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Condition 26
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 27
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Condition 28
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Condition 29
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Condition 30
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 31
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Condition 32
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Condition 1
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Condition 2
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 3
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Condition 4
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Condition 5
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
Condition 6
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Condition 7
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Condition 8
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 9
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 10
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 11
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Condition 12
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Condition 13
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Condition 14
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Condition 15
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Condition 16
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 17
n=17 participants at risk
1\) Lifestyle Core; 2) 12 Telephone Coaching Sessions
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
|
Condition 18
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 19
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 20
n=16 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 21
n=16 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 22
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 23
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
|
Condition 24
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 25
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
|
Condition 26
n=16 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 27
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 28
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 29
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 30
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 31
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
|
Condition 32
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 1
n=18 participants at risk
1\) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 2
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 3
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 4
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 5
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 6
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 7
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
|
Condition 8
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 9
n=18 participants at risk；n=19 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 10
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 11
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 12
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 13
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 14
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 15
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Injury, poisoning and procedural complications
severe head injury
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/19 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
Brain bleed
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/19 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
Other adverse events
| Measure |
Condition 16
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 17
n=17 participants at risk
1\) Lifestyle Core; 2) 12 Telephone Coaching Sessions
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
|
Condition 18
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 19
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 20
n=16 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 21
n=16 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 22
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 23
n=17 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
|
Condition 24
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 25
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
|
Condition 26
n=16 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 27
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 28
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 29
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 30
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 31
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
|
Condition 32
n=17 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 1
n=18 participants at risk
1\) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 2
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 3
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 4
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 5
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 6
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 7
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
|
Condition 8
n=18 participants at risk
1\) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
12 Telephone Coaching Sessions: Participants will receive 12 telephone coaching sessions
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 9
n=18 participants at risk；n=19 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
|
Condition 10
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 11
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 12
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Report to Primary Care Physician: Participants will have a report detailing their weight loss progress sent to their primary care physician
Text Messages: Participants will receive regular text messages
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 13
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Buddy Training: Participants will have a buddy that will be trained via webinars to be a supportive buddy
|
Condition 14
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Recommendations to use meal replacements: Participants will receive recommendations from their coach to use meal replacements
|
Condition 15
n=18 participants at risk
1\) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
24 Telephone Coaching Sessions: Participants will receive 24 telephone coaching sessions
Text Messages: Participants will receive regular text messages
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
urinary tract infection
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
blisters
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
mononucleosis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Product Issues
intolerance to meal replacements
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Psychiatric disorders
eating disorder
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Endocrine disorders
thyroid imbalance
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Endocrine disorders
thyroid cancer
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Eye disorders
anterior scleritis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Gastrointestinal disorders
stomach ache
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Gastrointestinal disorders
stomach ulcer
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Gastrointestinal disorders
constipation
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Gastrointestinal disorders
colitis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
General disorders
medication switch
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
General disorders
bicycle accident
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Immune system disorders
neutropenia
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
influenza
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
food poisoning
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
16.7%
3/18 • Number of events 3 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
sinus infection
|
16.7%
3/18 • Number of events 4 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
strep throat
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
common cold
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
bronchitis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
pneumonia
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
stomach flu
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
staph infection
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
general respiratory infection
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Infections and infestations
ear infection
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Psychiatric disorders
depression
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Renal and urinary disorders
bladder cancer
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Skin and subcutaneous tissue disorders
skin cancer
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Nervous system disorders
epilepsy
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Nervous system disorders
pinched nerve
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Nervous system disorders
seizure disorder
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Nervous system disorders
spinal stenosis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Respiratory, thoracic and mediastinal disorders
asthma
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Reproductive system and breast disorders
polycystic ovary syndrome
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Reproductive system and breast disorders
abnormal mammogram
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Reproductive system and breast disorders
uterine prolapse
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Reproductive system and breast disorders
breast cancer
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
osteoarthritis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
tendonitis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
plantar fasciitis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
degenerative disc disease
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
arthritis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Musculoskeletal and connective tissue disorders
capsulitis
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
dental procedure
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
skin surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
foot surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
hyperhidrosis surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
stomach surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
elbow surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
kidney stone surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Surgical and medical procedures
lasik eye surgery
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
muscle soreness
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
16.7%
3/18 • Number of events 4 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
joint soreness
|
16.7%
3/18 • Number of events 3 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
muscle strain
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
ankle sprain
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
fracture
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
6.2%
1/16 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
contusion
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
laceration
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
migraine
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
11.1%
2/18 • Number of events 3 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
muscle cramps
|
5.6%
1/18 • Number of events 2 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.9%
1/17 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
knee sprain
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
|
Injury, poisoning and procedural complications
mild concussion
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/16 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/17 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
5.6%
1/18 • Number of events 1 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
0.00%
0/18 • Adverse event data were collected from randomization to 6-month follow-up. All 562 participants in the study were enrolled between 2013 and 2017.
|
Additional Information
Bonnie Spring, PhD, ABPP
Northwestern University Feinberg School of Medicine
Phone: 312-908-2293
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place